Impact of computational structure-based predictive toxicology in drug discovery

Combinatorial Chemistry and High Throughput Screening

Volumn 14, Issue 5, 2011, Pages 417-426

  Mohan, Chethampadi Gopi ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

ADME T; CYP450; hERG; REACH; Toxicoinformatics

Indexed keywords

AMINOPHENAZONE; CISAPRIDE; CYTOCHROME P450; DEXFENFLURAMINE; DIPYRONE; ENCAINIDE; ETRETINATE; FENCAMFAMIN; FENFLURAMINE; GREPAFLOXACIN; IPRONIAZID; MIBEFRADIL; NEFAZODONE; PHENACETIN; PHENFORMIN; PHENOLPHTHALEIN; PHENYLPROPANOLAMINE; POTASSIUM CHANNEL HERG; ROFECOXIB; TEGASEROD; TERFENADINE; THALIDOMIDE; TIENILIC ACID; TOLCAPONE; TRIAZOLAM; TROGLITAZONE; VALDECOXIB; ZIMELDINE; ZOMEPIRAC;

AGRANULOCYTOSIS; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; BIRTH DEFECT; BRAIN HEMORRHAGE; CARCINOGENICITY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COMPUTER PROGRAM; DRUG ABUSE; DRUG ERUPTION; EOSINOPHILIA; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HEPATITIS; HUMAN; KIDNEY DISEASE; LACTIC ACIDOSIS; LIVER INJURY; LIVER TOXICITY; MATHEMATICAL ANALYSIS; MENTAL DISEASE; NONHUMAN; PERIPHERAL NEUROPATHY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; STROKE; STRUCTURE ANALYSIS; TERATOGENICITY; TOXICITY TESTING; TOXICOINFORMATICS; TOXICOLOGICAL PARAMETERS; VALVULAR HEART DISEASE;

ANIMALS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG DISCOVERY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS;

ANIMALIA;

EID: 79955745792     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620711795508395     Document Type: Article

References (84)

1. Cronin, M.T.; Livingstone, D.J. Predicting Chemical Toxicity and Fate. CRC Press, Boca Raton FL, USA, 2004.
2. Yu, H.; Adedoyin, A.; ADME-Tox in drug discovery: integration of experimental and computational technologies. Drug Discov. Today, 2003, 8, 852-861. (Pubitemid 37083343)
3. Maunz, A.; Helma, C. Prediction of toxic effects of pharmaceutical agents. In K. V. Balakin, editor, Pharmaceutical Data Mining: Approaches and Applications for Drug Discovery, New York, J. Wiley & Sons, Inc., 2009.
4. Cronin, M.T. In silico toxicology challenges for pharmaceuticals: complacency or controversy? Altern Lab Anim., 2009, 37, 453-456.
5. Ekins, S.; Williams, A.J. Precompetitive preclinical ADME/Tox data: Set it free on the web to facilitate computational model building to assist drug development. Lab. On A Chip, 2010, 10, 13-22.
6. Lagorce, D.; Sperandio, O.; Galons, H.; Miteva, M. A.; Villoutreix, B. O. FAFDrugs2: Free ADME/tox filtering tool to assist drug discovery and chemical biology projects. BMC Bioinformatics, 2008, 9, 396-405.
7. Adelina, M.V.; Thomas, G.O.; Paul, T.A. Toward a Comprehensive Molecular Design Framework for Reduced Hazard, Chem. Rev., 2010, 110, 5845-5882.
8. Travis, T.W.; Ramalakshmi, Y.C.; Xinjun, H.; Matthew, D.; Troutman, P.R.; Verhoest, A.V.; Yvonne, W. Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes, ACS Chem. Neurosci., 2010, 1, 420-434.
9. Ellison, C.M.; Madden, J.C.; Judson, P.; Cronin, M.T.D. Using In Silico Tools in a Weight of Evidence Approach to Aid Toxicological Assessment. Mol. Inf., 2010, 29, 97-110.
10. Vedani, A.; Smiesko, M. In silico toxicology in drug discovery - concepts based on three-dimensional models. Altern. Lab Anim., 2009, 37, 477-496.
11. http://ec.europa.eu/environment/chemicals/reach/publications-en.htm ) (accessed- 11-10-2010).
12. http://echa.europa.eu/home-en.asp (accessed- 10-10-2010).
13. Anon. European Commission JRC Report, 2006, http://ihcp.jrc.ec.europa.eu/ docs/ecb/REACHanimalfigures.pdf (accessed 10.10.2010).
14. Vonk, J.A.; Benigni, R.; Hewitt, M.; Nendza, M.; Segner, H.; van de Meent, D.; Cronin, M.T. The use of mechanisms and modes of toxic action in integrated testing strategies: the report and recommendations of a workshop held as part of the European Union OSIRIS Integrated Project. Altern. Lab. Anim., 2009, 37, 557-571.
15. Barry, H.; Nicki, D.; Christoph, H.; Micha, R.; Nina, J.; Vedrin, J.; Ivelina, N.; Romualdo, B.; Olga, T.; Stefan, K.; Tobias, G.; Fabian, B.; Joerg W.; Andreas, K.; Martin, G.; Andreas, M.;Haralambos, S.; Georgia, M.; Antreas, A.; Pantelis, S.; David, G.; Vladimir, P.; Dmitry, F.; Alexey, Z.; Alexey, L.; Tatyana, G.; Sergey, N.; Natalia, S.; Dmitry, D.; Sunil, C.; Indira, G.; Surajit, R.; Hitesh, P.; Sylvia, E. Collaborative development of predictive toxicology applications. J. Cheminform., 2010, 2, 1-29.
16. Divita, G.; Tamanna, G.; Mohan, C.G. Exploring QSTR and Toxicophore of hERG K+ channel blockers using GFA and HypoGen techniques. J. Mol. Graph. Model., 2008, 26, 966-976.
17. Mohan, C.G.; Tamanna, G.; Divita, G.; Ranajit, S. Computer Assisted Methods in Chemical Toxicity Prediction. Mini Rev. Med. Chem., 2007, 7, 499-507.
18. Mahendra, A.; Vivek, K.; Saravanan, P.; Mohan, C.G. Homology modeling and atomic level binding study of Leishmania MAPK with inhibitors. J. Mol. Model., 2010, 16, 475-488.
19. Pajeva, I.K.; Globisch, C.; Wiese, M. Comparison of the inward- and outward-open homology models and ligand binding of human Pglycoprotein. FEBS J., 2009, 276, 7016-7026.
20. Morrow, J.K.; Tian, L.; Zhang, S. Molecular networks in drug discovery. Crit. Rev. Biomed. Eng., 2010, 38, 143-156.
21. Hopkins, A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol., 2008, 4, 682-690.
22. Schrattenholz, A.; Groebe, K.; Soskic, V. Systems biology approaches and tools for analysis of interactomes and multi-target drugs. Methods Mol. Biol., 2010, 662, 29-58.
23. Combes, R.D.; Rodford, R.A. The Use of Expert Systems for Toxicity Prediction Illustrated with Reference to the DEREK Program, Cronin, M.T.D,; Livingstone, D.J. Ed.; Predicting Chemical Toxicity and Fate, CRC Press, Boca Raton FL, USA, 2004, 193-203.
24. TOPKAT (www.accelrys.com)
25. Gombar, V.K.; Silver, I.S.; Zhao, Z. Role of ADME characteristics in drug discovery and their in silico evaluation: in silico screening of chemicals for their metabolic stability. Curr. Top. Med. Chem., 2003, 3, 1205-1225.
26. Martin, P.P. Computer based methods for the prediction of chemical metabolism and biotransformation within biological organisms, Chapter 10, MTD Cronin and DJ Livingstone editions -Predicting chemical toxicity and fate. CRC Press, 2004.
27. Greene, N.; Fisk, L.; Naven, R.T.; Note, R.R.; Patel, M.L.; Pelletier, D.J. Developing structure-activity relationships for the prediction of hepatotoxicity. Chem. Res. Toxicol., 2010, 23, 1215-1222.
28. Hughes, J. D.; Blagg, J.; Price, D.A.; Bailey, S.; Decrescenzo, G.A.; Devraj, R.V.; Ellsworth, E.; Fobian, Y.M.; Gibbs, M.E.; Gilles, R.W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whitely, L.; Zhang, Y. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett., 2008, 18, 4872-4875.
29. Johnson, J.A.; Bootman, J.L. Drug-related morbidity and mortality. A cost-of-illness model. Arch. Int. Med., 1995, 155, 1949-1956.
30. Leape, L.L.; Brennan, T.A.; Laird, N.; Lawthers, A.G.; Localio, A.R.; Barnes, B.A.; Hebert, L.; Newhouse, J.P.; Weiler, P.C.; Hiatt, H.H. The nature of Adverse events in hopitalized patients. Results of the Harvard Medical Practice Study II. New J. Med., 1991, 324, 377-394.
31. Classen, D.C.; Pestotnik, S.L.; Evans, R.S.; Lloyd, J.F.; Burke, J.P. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. J. Am. Med. Assoc., 1997, 277, 301-306. (Pubitemid 27045010)
32. Thummel, K.E.; Wilkinson, G.R. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol., 1998, 38, 389-430. (Pubitemid 28231501)
33. Woosley, R.L.; Chen, Y.; Freiman, J.P.; Gillis, R.A. Mechanism of the cardiotoxic actions of terfenadine. J. Am. Med. Assoc., 1993, 269, 1532-1536. (Pubitemid 23086414)
34. Zarraga, I.G.E.; Schwarz, E.R. Coxibs and Heart Disease. J. Amer. Coll. Card., 2007, 49, 1-149.
35. Roth, B.L. "Drugs and valvular heart disease". N. Engl. J. Med., 2007, 356, 6-9.
36. Rothman, R.B.; Baumann, M.H. Serotonergic drugs and valvular heart disease. Expert. Opin. Drug Saf., 2009, 8, 317-329.
37. Friedman, M.A.; Woodcock, J.; Lumpkin, M.M.; Shuren, J.E.; Hass, A.E.; Thompson, L.J. The safety of newly approved medicines: do recent market removals mean there is a problem? J. Am. Med. Assoc., 1999, 281, 1728-1734. (Pubitemid 29226484)
38. Chyka, P.A.; McCommon, S.W. Reporting of adverse drug reactions by poison control centres in the US. Drug Saf., 2000, 23, 87-93. (Pubitemid 30455919)
39. Woosley, R.L.; Chen, Y.; Freiman, J.P.; Gillis, R.A. Mechanism of the cardiotoxic actions of terfenadine. J. Am. Med. Assoc., 1993, 269, 1532-1536. (Pubitemid 23086414)
40. Caraco, Y.; Sheller, J.; Wood, A.J. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J. Pharmacol. Exp. Ther., 1996, 278, 1165-1174. (Pubitemid 27166966)
41. Aklillu, E.; Persson, I.; Bertilsson, L.; Johansson, I.; Rodrigues, F.; Ingelman-Sundberg, M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther., 1996, 278, 441-446. (Pubitemid 27167124)
42. Branch, R.A.; Adedoyin, A.; Frye, R.F.; Wilson, J.W.; Romkes, M. In vivo modulation of CYP enzymes by quinidine and rifampin. Clin. Pharmacol. Ther., 2000, 68, 401-411.
43. Shin, J.G.; Kane, K.; Flockhart, D.A. Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced halo-peridol. Br. J. Clin. Pharmacol., 2001, 51, 45-52. (Pubitemid 32118819)
44. Shin, J.G.; Soukhova, N; Flockhart, D.A. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug. Metab. Dispos., 1999, 27, 1078-1084. (Pubitemid 29409646)
45. Bergstrom, R.F.; Peyton, A.L.; Lemberger, L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin. Pharmacol. Ther., 1992, 51, 239-248.
46. Leucht, S.; Hackl, H.J.; Steimer, W.; Angersbach, D.; Zimmer, R. Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients. Psychopharmacology (Berl), 2000, 147, 378-383. (Pubitemid 30048485)
47. Black, D.J.; Kunze, K.L.; Wienkers, L.C.; Gidal, B.E.; Seaton, T.L.; McDonnell, N.D; Evans, J.S.; Bauwens, J.E.; Trager, W.F. Warfarinfluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab. Dispos., 1996, 24, 422-428.
48. Piscitelli, S.C.; Burstein, A.H.; Chaitt, D.; Alfaro, R.M.; Falloon, J. Indinavir concentrations and St John's wort. Lancet, 2000, 355, 547-548. (Pubitemid 30088677)
49. Kane, G.C.; Lipsky, J.J. Drug-grapefruit juice interactions. Mayo Clin. Proc., 2000, 75, 933-942.
50. Lown, K.S.; Bailey, D.G.; Fontana, R.J.; Janardan, S.K.; Adair, C.H.; Fortlage, L.A.;Brown, M.B.; Guo, W.; Watkins, P.B. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest., 1997, 99, 2545-2553. (Pubitemid 27227734)
51. Van de Waterbeemd, H.; Gifford, E. ADMET in silico modelling: towards prediction paradise. Nat. Rev. Drug Discov., 2003, 2, 192-204. (Pubitemid 37361664)
52. De Groot Marcel, J. Designing better drugs: predicting cytochrome P450 metabolism. Drug Discov. Today, 2006, 11, 601-606.
53. Schuster, D.; Laggner, C.; Steindl, T.M.; Langer, T. Development and validation of an in silico P450 profiler based on pharmacophore models. Curr. Drug Discov. Tech., 2006, 3, 1-48.
54. Schuster, D.; Steindl, T.M.; Langer, T. Predicting drug metabolism induction in silico. Curr. Top. Med. Chem., 2006, 6, 1627-1640. (Pubitemid 44313417)
55. Klabunde, T.; Evers, A. GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects. Chembiochem: A Eur. J. Chem. Biol., 2005, 6, 876-889. (Pubitemid 40873749)
56. Aronov, A.M. Predictive in silico modeling for hERG channel blockers. Drug Discov. Today, 2005, 10, 149-155. (Pubitemid 40247813)
57. Rostami-Hodjegan, A.; Tucker, G.T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov., 2007, 6, 140-148. (Pubitemid 46745341)
58. Steindl, T.M.; Schuster, D.; Wolber, G.; Laggner, C.; Langer, T. Highthroughput structure-based pharmacophore modelling as a basis for successful parallel virtual screening. J. Comput.-Aided Mol. Des., 2006, 20, 703-715. (Pubitemid 46476941)
59. Steindl, T.M.; Schuster, D.; Laggner, C.; Chuang, K.; Hoffmann, R.D.; Langer, T. Parallel Screening and Activity Profiling with HIV Protease Inhibitor Pharmacophore Models. J. Chem. Inf. Model., 2007, 47, 563-571. (Pubitemid 46615958)
60. http://pubchem.ncbi.nlm.nih.gov/
61. Whitebread, S.; Hamon, J.; Bojanic, D.; Urban, L. In vitro safety pharmacology profiling: An essential tool for successful drug development. Drug Discovery Today, 2005, 10, 1421-1433. (Pubitemid 41483871)
62. Haney, S.A.; LaPan, P.; Pan, J.; Zhang, J. High-content screening moves to the front of the line. Drug Discov. Today, 2006, 11, 889-894. (Pubitemid 44403188)
63. Fuhr, U. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf., 1998, 18, 251-272. (Pubitemid 28177290)
64. Aronov, A.M.; Goldman, B.B. A model for identifying HERG K+ channel blockers. Bioorg. Med. Chem., 2004, 12, 2307-2315. (Pubitemid 38471715)
65. Pearlstein, R.A.; Vaz, R.J.; Kang, J.; Chen, X.L.; Preobrazhenskaya, M.; Shchekotikhin, A.E.; Korolev, A.M.; Lysenkova, L.N.; Miroshnikova, O.V.; Hendrix, J.; Rampe, D. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett., 2003, 13, 1829-1835. (Pubitemid 36561175)
66. Mitcheson, J.S.; Chen, J.; Lin, M.; Culberson, C.; Sanguinetti, M.C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. USA, 2000, 97, 12329-12333.
67. Sanguinetti, M.C.; Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. Nature, 2006, 440, 463-469.
68. Zunkler, B.J. Human ether-a-go-go-related (HERG) gene and ATPsensitive potassium channels as targets for adverse drug effects. Pharmacol. Ther., 2006, 112, 12-37. (Pubitemid 44339547)
69. Recanatini, M.; Poluzzi, E.; Masetti, M.; Cavalli, A.; De Ponti, F. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. Med. Res. Rev., 2005, 25, 133-166. (Pubitemid 40299844)
70. Rajamani, R.; Tounge, B.A.; Li, J.; Reynolds, C.H. A two-state homology model of the hERG K+ channel: application to ligand binding. Bioorg. Med. Chem. Lett., 2005, 15, 1737-1741. (Pubitemid 40312562)
71. Wang, Q.; Bowles, N.E.; Towbin, J.A. The molecular basis of long QT syndrome and prospects for therapy. Mol. Med. Today, 1998, 4, 382-388. (Pubitemid 28411032)
72. Cavalli, A.; Poluzzi, E.; De Ponti, F.; Recanatini, M. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J. Med. Chem., 2002, 45, 3844-3853. (Pubitemid 35024289)
73. Cianchetta, G.; Li, Y.; Kang, J.; Rampe, D.; Fravolini, A.; Cruciani, G.; Vaz, R.J. Predictive models for hERG potassium channel blockers. Bioorg. Med. Chem. Lett., 2005, 15, 3637-3642. (Pubitemid 40942074)
74. Coi, A.; Massarelli, I.; Murgia, L.; Saraceno, M.; Calderone, V.; Bianucci, A.M. Prediction of hERG potassium channel affinity by the CODESSA approach. Bioorg. Med. Chem., 2006, 14, 3153-3159.
75. Song, M.; Clark, M. Development and evaluation of an in silico model for hERG binding. J. Chem. Inf. Model., 2006, 46, 392-400. (Pubitemid 43282130)
76. Matyus, P.; Borosy, A.P.; Varro, A.; Papp, J.G.; Barlocco, D.; Cignarella, G. Development of pharmacophores for inhibitors of the rapid component of the cardiac delayed rectifier potassium current. Int. J. Quant. Chem., 1998, 69, 21-30. (Pubitemid 128566989)
77. Borosy, A.P.; Keseru, K.; Penzes, I.; Matyus, P. 3D QSAR study of class I antiarrhythmics. J. Mol. Struct., 2000, 503, 113-129.
78. Choe, H.; Nah, K.H.; Lee, S.N.; Lee, H.S.; Jo, S.H.; Leem, C.H.; Jang, Y.J. A novel hypothesis for the binding mode of HERG channel blockers. Biochem. Biophys. Res. Commun., 2006, 344, 72-78.
79. Du, L.P.; Tsai, K.C.; Li, M.Y.; You, Q.D.; Xia, L. The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents. Bioorg. Med. Chem. Lett., 2004, 14, 4771-4777. (Pubitemid 39490307)
80. Ekins, S.; Crumb, W.J.; Sarazan, R.D.; Wikel, J.H.; Wrighton, S.A. Three dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channels. J. Pharmacol. Exp. Ther., 2002, 301, 427-434. (Pubitemid 34429951)
81. Aronov, A.M. Common pharmacophores for uncharged human etherago-go-related gene (hERG) blockers. J. Med. Chem., 2006, 49, 6917-6921.
82. Aronov, A.M. Predictive in silico modeling for hERG channel blockers. Drug Discov. Today, 2005, 10, 149-155. (Pubitemid 40247813)
83. Sanchez-Capula, J.A.; Salinas-Stefanon, E.; Torres-Jacome, J.; Benavides-Haro, D.E.; Navarro-Polanco, R.A. Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes. J. Pharmacol. Exp. Ther., 2001, 297, 437-445. (Pubitemid 32242605)
84. Ficker, E.; Obejero-Paz, C.A.; Zhao, S.; Brown, A.M. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J. Biol. Chem., 2002, 277, 4989-4998. (Pubitemid 34968538)